Introduction to late presentation for HIV treatment in Europe

Antiviral Therapy

Volumn 15, Issue SUPPL. 1, 2010, Pages 1-2

  Antinori, Andrea ^a   Johnson, Margaret ^b   Moreno, Santiago ^c   Rockstroh, Jürgen K ^d   Yazdanpanah, Yazdan ^e  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSITY OF BONN   (Germany)

^e CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4+ T LYMPHOCYTE; DRUG EFFICACY; EARLY DIAGNOSIS; HEALTH CARE ORGANIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VIRUS DIAGNOSIS;

AIDS SERODIAGNOSIS; EUROPE; HEALTH POLICY; HIV INFECTIONS; HUMANS; PREVALENCE; RISK FACTORS; TIME FACTORS;

EID: 77952048123     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1521     Document Type: Review

References (15)

1. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71. (Pubitemid 351228129)
2. Panel on antiretroviral guidelines for adults and adolescents: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 01 December 2009. Accessed 12 January 2010.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
3. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
4. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
5. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009; 21:284-293.
6. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 Suppl 1:S3-S8. (Pubitemid 47312320)
7. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570-585. (Pubitemid 40204670)
8. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15 Suppl 1:3-8.
9. Moreno S, Mocroft A, d'Arminio Monforte A. Medical and societal consequences of late presentation. Antivir Ther 2010; 15 Suppl 1:9-15.
10. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
11. Yazdanpanah Y, Lange J, Gerstoft J, Cairns G. Early testing for HIV - how do we prevent late presentation? Antivir Ther 2010; 15 Suppl 1:17-24.
12. Mounier-Jack S, Nielsen S, Coker RJ. HIV testing strategies across European countries. HIV Med 2008; 9 Suppl 2:13-19. (Pubitemid 351819090)
13. Rockstroh JK, Gatell J, Landman R, Antinori A. Management of late-presenting patients with HIV infection. Antivir Ther 2010; 15 Suppl 1:25-30.
14. Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK. Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antivir Ther 2010; 15 Suppl 1:31-35.
15. HIV in Europe. HIV in Europe website (Updated 12 January 2010. Accessed 12 January 2010.) Available from http://www.hiveurope.eu/